Bionano Genomics Announces Extensive Lineup of Content at Association for Molecular Pathology ...
Bionano Genomics, Inc. (Nasdaq: BNGO) today announced its participation in the Association for Molecular Pathology (AMP) Annual Meeting and Expo 2022 with a broad range of content covering optical genome mapping’s (OGM) utility for research applications including prenatal and postnatal analysis, genetic disease and hematological malignancies
SAN DIEGO, Oct. 28, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced its participation in the Association for Molecular Pathology (AMP) Annual Meeting and Expo 2022 with a broad range of content covering optical genome mapping’s (OGM) utility for research applications including prenatal and postnatal analysis, genetic disease and hematological malignancies.
AMP’s Annual Meeting brings together industry, medical, and academic professionals to discuss advances in the field of molecular diagnostics. The AMP conference will be held November 1-5, 2022, in Phoenix, Arizona.
Scientific presentations and poster sessions from Bionano and collaborators include:SessionTitlePresenterPresentedCorporate WorkshopMaximizing Detection of Pathogenic Structural Variants Across Hematological Malignancies with Optical Genome MappingChaubey A., Sahajpal N., Kanagal-Shamanna R., Smith A. November 2, 2022
9:00-9:50 AM PDT
Room 229 ABCorporate WorkshopComprehensive Assessment of HRD From Next-Generation Sequencing and Optical Genome MappingChaubey A., Kanagal-Shamanna R., Kolhe R., Lum C. November 2, 2022
10:00-10:50 AM PDT
Room 229 ABPlenary SessionImplementation of Long-Read Sequencing and Optical Genome Mapping in the Cytogenetic LaboratorySmith A. November 4, 2022
3:45-5:15 PM PDT
See program for locationPlenary SessionNext Generation CytogenomicsSmith A., Duncavage E., Akkari Y., Hasserjian R. November 4, 2022
3:45-5:15 PM PDT
See program for locationPoster TitleAuthor/ Affiliation Even-Numbered Posters: Friday, November 4 | 9:15 AM – 10:15 AM
Odd-Numbered Posters: Saturday, November 5 | 9:15 AM – 10:15 AM Are we using the right tools to calculate homologous recombination deficiency (HRD) scores? Kolhe Lab
Augusta UniversityCompound heterozygous events in myeloid tumors: Next-generation approach with optical genome mapping and a 523-gene NGS panel Kolhe Lab
Augusta UniversityMosaic structural variation detection with optical genome mapping: Lower limit of detection study Kolhe Lab
Augusta UniversityBringing a new technology in CLIA laboratory: Our experience of clinical validation, getting AMA PLA code, and the Moldx Z-code for optical genome mapping for evaluation of hematological neoplasms Kolhe Lab
Augusta UniversityGoing beyond karyotyping and FISH: Impact of optical genome mapping (OGM) with additional clinically relevant information in 75 hematological malignancy cases Kolhe Lab
Augusta UniversityOptical genome mapping: a potential tier I test for prenatal diagnostic testing Kolhe Lab
Augusta UniversityClinical validation of optical genome mapping for postnatal application Kolhe Lab
Augusta UniversityRetrospective optical genome mapping analysis of FSHD1 and 2 negative patients with diminished methylation revealed exon deletions of SMCHD1 Stence Lab
University of IowaNGS copy number signatures in the assessment of cancers of unknown origin: Targeting therapy Lum Lab
Queens Medical CenterHigher resolution and accurate breakpoint determination of a balanced translocation by optical genome mapping Serrano M.
Bionano LaboratoriesOptical genome mapping workflow for somatic abnormality detection in multiple solid tumor types Yu J.
Bionano Genomics
“We are excited to see the highest number yet of presentations featuring OGM at AMP this year, demonstrating OGM’s utility for cutting-edge research applications in molecular pathology. We are also pleased to see sessions and posters covering the combination of OGM with NGS data to provide a more comprehensive picture of the genome,” commented Erik Holmlin, president and chief executive officer of Bionano.
More details on the conference can be found here.
About Bionano Genomics
Bionano Genomics is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company’s mission is to transform the way the world sees the genome through OGM solutions, diagnostic services and software. The Company offers OGM solutions for applications across basic, translational and clinical research. Through its Lineagen, Inc. d/b/a Bionano Laboratories business, the Company also provides diagnostic testing for patients with clinical presentations consistent with autism spectrum disorder and other neurodevelopmental disabilities. Through its BioDiscovery business, the Company also offers an industry-leading, platform-agnostic software solution, which integrates next-generation sequencing and microarray data designed to provide analysis, visualization, interpretation and reporting of copy number variants, single-nucleotide variants and absence of heterozygosity across the genome in one consolidated view. For more information, visit www.bionanogenomics.com, www.bionanolaboratories.com or www.biodiscovery.com
Forward-Looking Statements of Bionano Genomics
This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, the ability and utility of OGM to complement next generation sequencing (NGS) and provide a more comprehensive analysis of the genome for applications in genetic disease and cancer research. Each of these forward-looking statements involves risks and uncertainties. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the risks and uncertainties associated with: the impact of the COVID-19 pandemic on our business and the global economy; general market conditions; changes in the competitive landscape and the introduction of competitive technologies or improvements to existing technologies; failure of OGM to achieve useful complementarity with NGS; failure of OGM to be adopted for research applications; the ability of our OGM solutions to offer the anticipated benefits for and contributions to the areas of research reported in the presentations given and posters made available at the AMP Annual Meeting and Expo 2022; future study results contradicting the results reported in the presentations given and posters made available at the AMP Annual Meeting and Expo 2022; changes in our strategic and commercial plans; our ability to obtain sufficient financing to fund our strategic plans and commercialization efforts; the ability of medical and research institutions to obtain funding to support adoption or continued use of our technologies; and the risks and uncertainties associated with our business and financial condition in general, including the risks and uncertainties described in our filings with the Securities and Exchange Commission, including, without limitation, our Annual Report on Form 10-K for the year ended December 31, 2021 and in other filings subsequently made by us with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise.
CONTACTS
Company Contact:
Erik Holmlin, CEO
Bionano Genomics, Inc.
+1 (858) 888-7610
eholmlin@bionanogenomics.com
Investor Relations:
Amy Conrad
Juniper Point
+1 (858) 366-3243
amy@juniper-point.com
